MaxCyte Expects 2025 Core Revenue Between $29.5 Million and $29.6 Million
Core revenue in the fourth quarter is expected to be between $6.6 million and $6.7 million. Core revenue for the full year is expected to be between $29.5 million and $29.6 million. Strategic Platform License program-related revenue in the fourth quarter is expected to be between $0.4 million and $0.6 million. SPL program-related revenue for the full year is expected to be between $3.3 million and $3.5 million. Total cash, cash equivalents, and investments as of December 31, 2025, is expected to be approximately $155.6 million. "2025 was a challenging, but productive year at MaxCyte. We worked through a difficult macro environment, including rationalization of programs and inventory management from a few SPL customers, however, we reported preliminary core revenue that was in-line with our guidance range," said Maher Masoud, President and CEO of MaxCyte. "We also made substantial and targeted progress in strategically aligning our resources and improving our cost structure to drive efficient growth and scale MaxCyte towards profitability in the future." "We are heading into 2026 with substantial cash, greatly reduced annual burn, and a leaner and more focused organization with new offerings being launched early in the year. We remain as excited as ever by the opportunity presented by our SPLs, and SPL pipeline, and the continued expansion of our SeQure services, and expect to return to revenue growth in the second half of the year."
Trade with 70% Backtested Accuracy
Analyst Views on MXCT
About MXCT
About the author
Cellares Appoints New CCO to Support 2026 Clinical Trials
- Executive Appointment: Cellares has appointed Ali Soleymannezhad as Chief Commercial Officer, who brings over 20 years of commercialization experience in cell therapy and bioprocessing, aimed at driving the company's global commercial strategy in preparation for clinical trials in 2026.
- Global Partnership Agreements: Cellares has signed multiple global manufacturing agreements with partners including Bristol Myers Squibb and Kite, establishing its leadership in cell therapy manufacturing and laying the groundwork for a future IPO.
- Technological Innovation: Cellares' Cell ShuttleTM has received FDA's Advanced Manufacturing Technology designation, providing expedited review and regulatory support to lower manufacturing costs and accelerate global market entry for cell therapies.
- Market Expansion: Cellares plans to establish a network of IDMO Smart Factories across the U.S., Europe, and Japan, which is expected to increase the batch output of each factory by tenfold, thereby meeting global patient demand for cell therapies.
MaxCyte Unveils Operational Restructuring Aimed at Cost Reduction and Faster Profitability
Workforce Reduction Announcement: MaxCyte, Inc. is restructuring its operations, resulting in a 34% reduction of its global workforce to align resources with strategic priorities, aiming for annualized savings of approximately $13.6 million.
Financial Outlook: The company anticipates flat to a 10% decline in core revenue for 2025 compared to 2024, while expecting around $5 million in SPL program-related revenue and a year-end cash position of at least $155 million.
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analyst Downgrades: Several Wall Street analysts downgraded their ratings on various companies, including The Trade Desk, C3.ai, Aspen Aerogels, MaxCyte, and Universal Electronics, with significant reductions in price targets.
Current Stock Performance: As of the latest market close, shares of these companies showed varying performance, with The Trade Desk at $54.23, C3.ai at $22.13, Aspen Aerogels at $7.55, MaxCyte at $1.38, and Universal Electronics at $5.00.
BTIG Downgrades MaxCyte to Neutral
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte and Adicet Bio Collaboration: MaxCyte has signed a strategic platform license with Adicet Bio, granting them rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for developing gamma delta T cell therapies aimed at treating cancer and autoimmune diseases.
Advancements in Cell Therapy: The collaboration highlights the potential of non-viral gene editing combined with scalable production methods to enhance the efficiency and accessibility of next-generation cell therapies.
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
Strategic Partnership Announcement: MaxCyte, Inc. has signed a Strategic Platform License Agreement with Anocca AB to utilize its Flow Electroporation® technology and ExPERT™ platform for the development of T-cell receptor engineered therapies.
Regulatory Compliance and Development Focus: Anocca has received GMP compliance certification for its cell therapy production facility and is advancing clinical development of its lead program targeting advanced pancreatic cancer, enhanced by MaxCyte's scalable technology platform.
Cellares Appoints New CCO to Support 2026 Clinical Trials
- Executive Appointment: Cellares has appointed Ali Soleymannezhad as Chief Commercial Officer, who brings over 20 years of commercialization experience in cell therapy and bioprocessing, aimed at driving the company's global commercial strategy in preparation for clinical trials in 2026.
- Global Partnership Agreements: Cellares has signed multiple global manufacturing agreements with partners including Bristol Myers Squibb and Kite, establishing its leadership in cell therapy manufacturing and laying the groundwork for a future IPO.
- Technological Innovation: Cellares' Cell ShuttleTM has received FDA's Advanced Manufacturing Technology designation, providing expedited review and regulatory support to lower manufacturing costs and accelerate global market entry for cell therapies.
- Market Expansion: Cellares plans to establish a network of IDMO Smart Factories across the U.S., Europe, and Japan, which is expected to increase the batch output of each factory by tenfold, thereby meeting global patient demand for cell therapies.
MaxCyte Unveils Operational Restructuring Aimed at Cost Reduction and Faster Profitability
Workforce Reduction Announcement: MaxCyte, Inc. is restructuring its operations, resulting in a 34% reduction of its global workforce to align resources with strategic priorities, aiming for annualized savings of approximately $13.6 million.
Financial Outlook: The company anticipates flat to a 10% decline in core revenue for 2025 compared to 2024, while expecting around $5 million in SPL program-related revenue and a year-end cash position of at least $155 million.
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analyst Downgrades: Several Wall Street analysts downgraded their ratings on various companies, including The Trade Desk, C3.ai, Aspen Aerogels, MaxCyte, and Universal Electronics, with significant reductions in price targets.
Current Stock Performance: As of the latest market close, shares of these companies showed varying performance, with The Trade Desk at $54.23, C3.ai at $22.13, Aspen Aerogels at $7.55, MaxCyte at $1.38, and Universal Electronics at $5.00.
BTIG Downgrades MaxCyte to Neutral
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte and Adicet Bio Collaboration: MaxCyte has signed a strategic platform license with Adicet Bio, granting them rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for developing gamma delta T cell therapies aimed at treating cancer and autoimmune diseases.
Advancements in Cell Therapy: The collaboration highlights the potential of non-viral gene editing combined with scalable production methods to enhance the efficiency and accessibility of next-generation cell therapies.
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
Strategic Partnership Announcement: MaxCyte, Inc. has signed a Strategic Platform License Agreement with Anocca AB to utilize its Flow Electroporation® technology and ExPERT™ platform for the development of T-cell receptor engineered therapies.
Regulatory Compliance and Development Focus: Anocca has received GMP compliance certification for its cell therapy production facility and is advancing clinical development of its lead program targeting advanced pancreatic cancer, enhanced by MaxCyte's scalable technology platform.
